Camila Coelho, PhD MBA
@camilahcoelho.bsky.social
Human B cell responses to emerging pathogens 🦠
Icahn School of Medicine at Mount Sinai, NYC 🏙 🚕 🗽🍎
www.coelholab.com
Icahn School of Medicine at Mount Sinai, NYC 🏙 🚕 🗽🍎
www.coelholab.com
August 27, 2025 at 8:36 PM
Reposted by Camila Coelho, PhD MBA
Reposted by Camila Coelho, PhD MBA
4/ Structural studies revealed all 3 mAbs target a highly conserved epitope in the A35 dimer groove, shared across orthopoxviruses. This explains their breadth and potency.
August 26, 2025 at 3:55 PM
4/ Structural studies revealed all 3 mAbs target a highly conserved epitope in the A35 dimer groove, shared across orthopoxviruses. This explains their breadth and potency.
Reposted by Camila Coelho, PhD MBA
7/ Together, our findings establish A35 as a critical therapeutic target for mpox and related orthopoxviruses, paving the way for next-generation antibody therapies and improved vaccines.
August 26, 2025 at 3:55 PM
7/ Together, our findings establish A35 as a critical therapeutic target for mpox and related orthopoxviruses, paving the way for next-generation antibody therapies and improved vaccines.
🙌 This work was a major collaboration with incredible colleagues across the US, and we’re grateful for Mount Sinai's support.
#Mpox #Antibodies #Immunology
[9/9]
#Mpox #Antibodies #Immunology
[9/9]
August 26, 2025 at 3:29 PM
🙌 This work was a major collaboration with incredible colleagues across the US, and we’re grateful for Mount Sinai's support.
#Mpox #Antibodies #Immunology
[9/9]
#Mpox #Antibodies #Immunology
[9/9]
💡 Translational highlight: In mpox patients, polyclonal antibodies targeting this same A35 groove were enriched and correlated with better outcomes (shorter symptoms, no hospitalization).
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]
August 26, 2025 at 3:29 PM
💡 Translational highlight: In mpox patients, polyclonal antibodies targeting this same A35 groove were enriched and correlated with better outcomes (shorter symptoms, no hospitalization).
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]
Structural studies revealed all these mAbs, despite very different binding loops, converge on the groove formed by the A35 dimer.
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]
August 26, 2025 at 3:29 PM
Structural studies revealed all these mAbs, despite very different binding loops, converge on the groove formed by the A35 dimer.
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]
How do they work?
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]
August 26, 2025 at 3:29 PM
How do they work?
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]
Treatment worked at just ~5 mg/kg...that’s 10x lower than the antibody doses used during recent Ebola outbreaks.
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]
August 26, 2025 at 3:29 PM
Treatment worked at just ~5 mg/kg...that’s 10x lower than the antibody doses used during recent Ebola outbreaks.
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]
✨ In collaboration with Ian Wilson, Bernie Moss, @carolilucas.bsky.social, @mschotsaert.bsky.social @vivianasimonlab.bsky.social, that’s exactly what we did!
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]
August 26, 2025 at 3:29 PM
✨ In collaboration with Ian Wilson, Bernie Moss, @carolilucas.bsky.social, @mschotsaert.bsky.social @vivianasimonlab.bsky.social, that’s exactly what we did!
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]
This led us to hypothesize: if we could map where strong anti-A35 antibodies bind (the epitope), we could uncover urgently needed therapeutics and reveal viral weak spots that vaccines could target.
[3/9]
[3/9]
August 26, 2025 at 3:29 PM
This led us to hypothesize: if we could map where strong anti-A35 antibodies bind (the epitope), we could uncover urgently needed therapeutics and reveal viral weak spots that vaccines could target.
[3/9]
[3/9]
💡 In 2023, our lab showed (PMID: 37475115) that people infected with mpox had unusually high antibody levels against A35, a surface protein of MPXV.
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]
August 26, 2025 at 3:29 PM
💡 In 2023, our lab showed (PMID: 37475115) that people infected with mpox had unusually high antibody levels against A35, a surface protein of MPXV.
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]